Results 201 to 210 of about 15,550 (253)
PUNTA AL LLAPIS. Tractament de la claudicació intermitent. Quin paper hi juga el cilostazol? [PDF]
Llobera, À.
core
Successful Clazosentan Therapy for Subarachnoid Hemorrhage after Coil Embolization of Ruptured Posterior Cerebral Artery Aneurysm in a Patient with Moyamoya Disease: A Case Report. [PDF]
NMC Case Rep JUchino H +5 more
europepmc +1 more source
Cilostazole versus clopidogrel in acute large-vessel moderate and moderate-to-severe ischemic stroke: a randomized controlled trial. [PDF]
Neurol SciAhmed SR +14 more
europepmc +1 more source
Effects of Cilostazol and Aspirin on Diabetic Foot Ulcer and Peripheral Artery Disease: A Retrospective Study. [PDF]
CureusJayalal JA, Kumar S, Mohan A.
europepmc +1 more source
Efficacy and safety of antiplatelet therapy for secondary prevention of small subcortical infarction: A systematic review and network meta-analysis. [PDF]
Eur Stroke JFeng X, Du J, Qu T, Xu S, Zhu W.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs & Aging, 1999
Cilostazol is an antiplatelet agent with vasodilating properties that has been used in the treatment of patients with peripheral ischaemia such as intermittent claudication. The drug inhibits platelet aggregation induced by ADP, collagen and arachidonic acid.
E M, Sorkin, A, Markham
+6 more sources
Cilostazol is an antiplatelet agent with vasodilating properties that has been used in the treatment of patients with peripheral ischaemia such as intermittent claudication. The drug inhibits platelet aggregation induced by ADP, collagen and arachidonic acid.
E M, Sorkin, A, Markham
+6 more sources
American Journal of Health-System Pharmacy, 2002
Cilostazol is a phosphodiesterase III inhibitor that has been shown to be effective for treatment of symptomatic intermittent claudication. It is generally well tolerated, but is contraindicated in patients with severe heart failure because of the potential detrimental effects demonstrated by other agents in the same class.
+7 more sources
Cilostazol is a phosphodiesterase III inhibitor that has been shown to be effective for treatment of symptomatic intermittent claudication. It is generally well tolerated, but is contraindicated in patients with severe heart failure because of the potential detrimental effects demonstrated by other agents in the same class.
+7 more sources